Our Science

OUR SCIENCE

Congress Presentations

This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.*

SITC 2026 | Phoenix, Arizona

Nov 4 - 8, 2026

Poster
Innate and Adaptive Immune Responses and Antitumor Activity Associated with ARV-6723, a PROTAC HPK1 Degrader, in Exhausted/Post-Immune Checkpoint Inhibitor (ICI) Preclinical Settings

AC Van Acker et al.

VIEW MATERIAL

SITC 2026 | Phoenix, Arizona

Nov 4 - 8, 2026

Poster
Trial in Progress: A Phase 1/2 Open-label Study of ARV-6723, an Oral PROTAC HPK1 Degrader, as Monotherapy or in Combination With an Anti-PD-1 Antibody in Patients With Advanced Solid Tumors

B Henick et al.

VIEW MATERIAL

MDS 2026 | Seoul, South Korea

Oct 4 - 8, 2026

Poster
Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data

K Fraser et al.

VIEW MATERIAL

MDS 2026 | Seoul, South Korea

Oct 4 - 8, 2026

Presentation
Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data

K Fraser et al.

VIEW MATERIAL

WMS 2026 | Hiroshima, Japan

Sep 29 - Oct 3, 2026

Poster
Phase 1 Study of a PROTAC PolyQ-AR Degrader (ARV-027) in Healthy Participants and Participants With Spinal and Bulbar Muscular Atrophy

J Gregory et al.

VIEW MATERIAL

AAIC 2026 | London, United Kingdom

Jul 12 - 15, 2026

Poster
PROTAC LRRK2 Degraders Reduce Pathological Tau and Modulate Endolysosomal–Neuroinflammatory Pathways in Translational Model Systems

D Gorka et al.

VIEW MATERIAL

FASEB 2026 | Louisville, KY

Jun 1 - 4, 2026

Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCL

W Wu et al.

VIEW MATERIAL

ASCO 2026 | Chicago, IL

May 29 - Jun 2, 2026

Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCL

M Hutchings et al.

VIEW MATERIAL

AACR 2026 | San Diego, CA

Apr 17 - 22, 2026

Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCL

M Hutchings et al.

VIEW MATERIAL
1 2 3 … 10

* Vepdegestrant (VEPPANU™) is licensed to Rigel Pharmaceuticals, which holds the exclusive global development, manufacturing, and commercialization rights.